BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Decrease in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 1,900 shares, a drop of 61.2% from the January 15th total of 4,900 shares. Based on an average trading volume of 129,600 shares, the short-interest ratio is presently 0.0 days.

BriaCell Therapeutics Stock Down 15.7 %

BriaCell Therapeutics stock traded down $0.02 on Thursday, reaching $0.11. 33,750 shares of the stock were exchanged, compared to its average volume of 109,290. The firm has a fifty day moving average price of $0.24 and a two-hundred day moving average price of $0.27. BriaCell Therapeutics has a twelve month low of $0.08 and a twelve month high of $1.89.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.